i-manager Publications

Liquid Nano Crystals: A New Frontier in Drug Delivery

Bondili Sadhana*

Department of Pharmaceutics, Gokaraju Rangaraju College of Pharmacy, Hyderabad, India.

Periodicity:September - December'2024
DOI : https://doi.org/10.26634/jls.3.3.21602

Abstract

The field of drug delivery has witnessed significant advancements with the emergence of nanotechnology. Among the innovative nanostructures, liquid Nano crystals have garnered attention as promising carriers for therapeutic agents. Liquid Nano crystals, composed of lipids and surfactants, exhibit unique properties that make them suitable for overcoming challenges associated with conventional drug formulations. This paper aims to provide an overview of the applications and advantages of liquid Nano crystals in drug delivery. By exploring their versatile formulations, enhanced bioavailability, and targeted delivery capabilities, we highlight the potential of liquid Nano crystals to revolutionize drug delivery strategies. Liquid Nano crystals offer versatility in drug formulations, accommodating both hydrophobic and hydrophilic drugs. Their Nano scale size contributes to improved bioavailability, addressing challenges associated with poorly water-soluble drugs. Surface modifications enable targeted drug delivery, enhancing therapeutic efficacy while minimizing side effects. Liquid Nano crystals can be engineered for sustained and controlled release, providing prolonged drug release profiles. Liquid Nano crystals represent a promising avenue in drug delivery, Ongoing research and development in this field continue to explore novel applications and address challenges, fostering the evolution of liquid Nano crystals as a key player in the future of drug delivery systems.

Keywords

Liquid Nano Crystals, Combination Therapy, Personalized Medicine, Cubosomes.

How to Cite this Article?

Sadhana, B. (2024). Liquid Nano Crystals: A New Frontier in Drug Delivery. i-manager’s Journal on Life Sciences, 3(3), 19-35. https://doi.org/10.26634/jls.3.3.21602

References

[1]. Abdelaziz, H. M., Elzoghby, A. O., Helmy, M. W., Samaha, M. W., Fang, J. Y., & Freag, M. S. (2019). Liquid crystalline assembly for potential combinatorial chemo–herbal drug delivery to lung cancer cells. International Journal of Nanomedicine, 499-517.

[2]. Agrawal, G. P., Maheshwari, R. K., & Mishra, P. (2022). Solubility enhancementofcefixime trihydrate by solid dispersions using hydrotropic solubilization technique and t h ei r ch ar act er i z at i on. B razil i an Journal of Pharmaceutical Sciences, 58, e18553.

[3]. Aibani, N., da Costa, P. F., Masterson, J., Marino, N., Raymo, F. M., Callan, J., & Callan, B. (2017). The integration of triggered drug delivery with real time quantification using FRET; Creating a super 'smart'drug delivery system. Journal of Controlled Release, 264, 136- 144.

[4]. Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews, 65(1), 36-48.

[5]. Bae, Y. H., & Park, K. (2011). Targeted drug delivery to tumors: Myths, reality and possibility. Journal of Controlled Release, 153(3), 198-205.

[6]. Beloqui, A., del Pozo-Rodríguez, A., Isla, A., Rodríguez-Gascón, A., & Solinís, M. Á. (2017). Nanostructured lipid carriers as oral delivery systems for poorly soluble drugs. Journal of Drug Delivery Science and Technology, 42, 144-154.

[7]. Beloqui, A., Solinís, M. Á., Rodríguez-Gascón, A., Almeida, A. J., & Préat, V. (2016). Nanostructured lipid carriers: Promising drug delivery systems for future clinics. Nanomedicine: Nanotechnology, Biology and Medicine, 12(1), 143-161.

[8]. Blanco, E., Shen, H., & Ferrari, M. (2015). Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nature Biotechnology, 33(9), 941-951.

[9]. Cabral, H., Matsumoto, Y., Mizuno, K., Chen, Q., Murakami, M., Kimura, M., & Kataoka, K. (2011). Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nature Nanotechnology, 6(12), 815-823.

[10]. Chakraborty, S., Liao, I. C., Adler, A., & Leong, K. W. (2009). Electrohydrodynamics: A facile technique to fabricate drug delivery systems. Advanced Drug Delivery Reviews, 61(12), 1043-1054.

[11]. Chen, Y., Chen, H., & Shi, J. (2013). In vivo bio-safety evaluations and diagnostic/therapeutic applications of chemically designed mesoporous silica nanoparticles. Advanced Materials, 25(23), 3144-3176.

[12]. Coles, H., & Morris, S. (2010). Liquid-crystal lasers. Nature Photonics, 4(10), 676-685.

[13]. Danhier, F., Feron, O., & Préat, V. (2010). To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. Journal of Controlled Release, 148(2), 135-146.

[14]. Davis, M. E., Chen, Z., & Shin, D. M. (2008). Nanoparticle therapeutics: An emerging treatment modality for cancer. Nature Reviews Drug Discovery, 7(9), 771-782.

[15]. Decuzzi, P., Godin, B., Tanaka, T., Lee, S. Y., Chiappini, C., Liu, X., & Ferrari, M. J. J. O. C. R. (2010). Size and shape effects in the biodistribution of intravascularly injected particles. Journal of Controlled Release, 141(3), 320-327.

[16]. Duan, X., & Li, Y. (2013). Physicochemical characteristics of nanoparticles affect circulation, biodistribution, cellular internalization, and trafficking. Small, 9(9-10), 1521-1532.

[17]. Farokhzad, O. C., & Langer, R. (2009). Impact of nanotechnology on drug delivery. ACS Nano, 3(1), 16-20.

[18]. Fenton, O. S., Olafson, K. N., Pillai, P. S., Mitchell, M. J., & Langer, R. (2018). Advances in biomaterials for drug delivery. Advanced Materials, 30(29), 1705328.

[19]. Florek, J., Caillard, R., & Kleitz, F. (2017). Evaluation of mesoporous silica nanoparticles for oral drug delivery–current status and perspective of MSNs drug carriers. Nanoscale, 9(40), 15252-15277.

[20]. Gref, R., Minamitake, Y., Peracchia, M. T., Trubetskoy, V., Torchilin, V., & Langer, R. (1994). Biodegradable long- circulating polymeric nanospheres. Science, 263(5153), 1600-1603.

[21]. Guo, S., & Huang, L. (2011). Nanoparticles escaping RES and endosome: Challenges for siRNA delivery for cancer therapy. Journal of Nanomaterials, 2011(1), 742895.

[22]. Hrkach, J., Von Hoff, D., Ali, M. M., Andrianova, E., Auer, J., Campbell, T., & Zale, S. (2012). Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Science Translational Medicine, 4(128), 128ra39-128ra39.

[23]. Hua, S. (2015). Lipid-based nano-delivery systems for skin delivery of drugs and bioactives. Frontiers in Pharmacology, 6, 219.

[24]. Jhaveri, J., Raichura, Z., Khan, T., Momin, M., & Omri, A. (2021). Chitosan nanoparticles-insight into properties, functionalization and applications in drug delivery and theranostics. Molecules, 26(2), 272.

[25]. Kamaly, N., Xiao, Z., Valencia, P. M., Radovic- Moreno, A. F., & Farokhzad, O. C. (2012). Targeted polymeric therapeutic nanoparticles: Design, development and clinical translation. Chemical Society Reviews, 41(7), 2971-3010.

[26]. Khan, A. R., Liu, M., Khan, M. W., & Zhai, G. (2017). Progress in brain targeting drug delivery system by nasal route. Journal of Controlled Release, 268, 364-389.

[27]. Khan, M. I., Hossain, M. I., Hossain, M. K., Rubel, M. H. K., Hossain, K. M., Mahfuz, A. M. U. B., & Anik, M. I. (2022). Recent progress in nanostructured smart drug delivery systems for cancer therapy: A review. ACS Applied Bio Materials, 5(3), 971-1012.

[28]. Khan, S., Baboota, S., Ali, J., Khan, S., Narang, R. S., & Narang, J. K. (2015). Nanostructured lipid carriers: An emerging platform for improving oral bioavailability of lipophilic drugs. International Journal of Pharmaceutical Investigation, 5(4), 182.

[29]. Kievit, F. M., & Zhang, M. (2011). Surface engineering of iron oxide nanoparticles for targeted cancer therapy. Accounts of Chemical Research, 44(10), 853-862.

[30]. Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012). Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress. Journal of Controlled Release, 161(2), 175-187.

[31]. Li, S. D., & Huang, L. (2008). Pharmacokinetics and bi odi s t r i bu t i on of n an opar t i cl es. Molecular Pharmaceutics, 5(4), 496-504.

[32]. Li, Z., Tan, S., Li, S., Shen, Q., & Wang, K. (2017). Cancer drug delivery in the nano era: An overview and perspectives. Oncology Reports, 38(2), 611-624.

[33]. Liu, J. S., Wang, J. H., Zhou, J., Tang, X. H., Xu, L., Shen, T., & Hong, Z. (2014a). Enhanced brain delivery of lamotrigine with Pluronic® P123-based nanocarrier. International Journal of Nanomedicine (pp. 3923-3935).

[34]. Liu, J., Huang, Y., Kumar, A., Tan, A., Jin, S., Mozhi, A., & Liang, X. J. (2014b). PH-sensitive nano-systems for drug delivery in cancer therapy. Biotechnology Advances, 32(4), 693-710.

[35]. Madheswaran, T., Kandasamy, M., Bose, R. J., & Karuppagounder, V. (2019). Current potential and challenges in the advances of liquid crystalline nanoparticles as drug delivery systems. Drug Discovery Today, 24(7), 1405-1412.

[36]. Makadia, H. K., & Siegel, S. J. (2011). Poly lactic-co- glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers, 3(3), 1377-1397.

[37]. Mezzenga, R., Meyer, C., Servais, C., Romoscanu, A. I., Sagalowicz, L., & Hayward, R. C. (2005). Shear rheology of lyotropic liquid crystals: A case study. Langmuir, 21(8), 3322-3333.

[38]. Mitov, M. (2017). Cholesteric liquid crystals in living matter. Soft Matter, 13(23), 4176-4209.

[39]. Mo, J., Milleret, G., & Nagaraj, M. (2017). Liquid crystal nanoparticles for commercial drug delivery. Liquid Crystals Reviews, 5(2), 69-85.

[40]. Müller-Goymann, C. C. (2004). Physicochemical characterization of colloidal drug delivery systems such as reverse micelles, vesicles, liquid crystals and nanoparticles for topical administration. European Journal of Pharmaceutics and Biopharmaceutics, 58(2), 343-356.

[41]. Mura, S., Nicolas, J., & Couvreur, P. (2013). Stimuli- responsive nanocarriers for drug delivery. Nature Materials, 12(11), 991-1003.

[42]. Neha, S. L., Mishra, A. K., Rani, L., Paroha, S., Dewangan, H. K., & Sahoo, P. K. (2023). Design and evaluations of a nanostructured lipid carrier loaded with dopamine hydrochloride for intranasal bypass drug del i v er y i n Par k i n s on ' s di s eas e. Journal of Microencapsulation, 40(8), 599-612.

[43]. Nieto González, N., Obinu, A., Rassu, G., Giunchedi, P., & Gavini, E. (2021). Polymeric and lipid nanoparticles: Which applications in pediatrics?. Pharmaceutics, 13(5), 670.

[44]. Nnamani, P. O., Hansen, S., Windbergs, M., & Lehr, C. M. (2014). Development of artemether-loaded nanostructured lipid carrier (NLC) formulation for topical application. International Journal of Pharmaceutics, 477(1-2), 208-217.

[45]. Noël, C., & Navard, P. (1991). Liquid crystal polymers. Progress in Polymer Science, 16(1), 55-110.

[46]. Obaidat, R. M., Khanfar, M., & Ghanma, R. (2019). A comparative solubility enhancement study of cefixime trihydrate using different dispersion techniques. AAPS PharmSciTech, 20, 1-13.

[47].Parveen, S., Misra, R., & Sahoo, S. K. (2017). Nanoparticles: A boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine in Cancer (pp. 47-98).

[48].Patel, D., Kesharwani, R., & Gupta, S. (2015). Development & screening approach for lipid nanoparticle: A review. Asian Journal of Pharmaceutical Research and Development (pp. 1-7).

[49].Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2020). Nanocarriers as an emerging platform for cancer therapy. Nano-Enabled Medical Applications (pp. 61-91).

[50]. Peer, D., Park, E. J., Morishita, Y., Carman, C. V., & Shimaoka, M. (2008). Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science, 319(5863), 627-630.

[51]. Sagalowicz, L., Leser, M. E., Watzke, H. J., & Michel, M. (2006). Monoglyceride self-assembly structures as delivery vehicles. Trends in Food Science & Technology, 17(5), 204-214.

[52]. Sanna, V., Pala, N., & Sechi, M. (2014). Targeted therapy using nanotechnology: Focus on cancer. International Journal of Nanomedicine (pp. 467-483).

[53]. Sant, S., Tao, S. L., Fisher, O. Z., Xu, Q., Peppas, N. A., & Khademhosseini, A. (2012). Microfabrication technologies for oral drug delivery. Advanced Drug Delivery Reviews, 64(6), 496-507.

[54]. Soppimath, K. S., Aminabhavi, T. M., Kulkarni, A. R., & Rudzinski, W. E. (2001). Biodegradable polymeric nanoparticles as drug delivery devices. Journal of Controlled Release, 70(1-2), 1-20.

[55]. Tan, J. S. L., Roberts, C., & Billa, N. (2020). Pharmacokinetics and tissue distribution of an orally administered mucoadhesive chitosan- coated amphotericin B-Loaded nanostructured lipid carrier (NLC) in rats. Journal of Biomaterials Science, Polymer Edition, 31(2), 141-154.

[56].Teng, L. H., Kumar, J. R., Leng, L., MVRA, M. S., & Kanagambikai, R. (2015). Nanoparticle loaded thermosensitive nasal in-situ gels for delivery of loratadine: In-vitro & in-vivo evaluation studies. Rapports De Pharmacie, 1(1), 17-27.

[57]. Torchilin, V. P. (2006). Multifunctional nanocarriers. Advanced Drug Delivery Reviews, 58(14), 1532-1555.

[58]. Wang, J. J., Zeng, Z. W., Xiao, R. Z., Xie, T., Zhou, G. L., Zhan, X. R., & Wang, S. L. (2011). Recent advances of chitosan nanoparticles as drug carriers. International Journal of Nanomedicine, 765-774.

[59]. Wang, Y., Zhao, Q., Han, N., Bai, L., Li, J., Liu, J., & Wang, S. (2015). Mesoporous silica nanoparticles in drug delivery and biomedical applications. Nanomedicine: Nanotechnology, Biology and Medicine, 11(2), 313-327.

[60]. Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. (2016). Analysis of nanoparticle delivery to tumours. Nature Reviews Materials, 1(5), 1-12.

[61]. Yellepeddi, V. K., Joseph, A., & Nance, E. (2019). Pharmacokinetics of nanotechnology- based formulations in pediatric populations. Advanced Drug Delivery Reviews, 151, 44-55.

[62]. Zeng, N., Gao, X., Hu, Q., Song, Q., Xia, H., Liu, Z., & Fang, L. (2012). Lipid-based liquid cr ystalline nanoparticles as oral drug delivery vehicles for poorly water-soluble drugs: Cellular interaction and in vivo absorption. International Journal of Nanomedicine, 3703-3718.

[63]. Zhang, L., Gu, F. X., Chan, J. M., Wang, A. Z., Langer, R. S., & Farokhzad, O. C. (2008). Nanoparticles in medicine: Therapeutic applications and developments. Clinical Pharmacology & Therapeutics, 83(5), 761-769.

[64]. Zhao, Y., Trewyn, B. G., Slowing, I. I., & Lin, V. S. Y. (2009). Mesoporous silica nanoparticle-based double drug delivery system for glucose-responsive controlled release of insulin and cyclic AMP. Journal of the American Chemical Society, 131(24), 8398-8400.

Liquid Nano Crystals: A New Frontier in Drug Delivery

Abstract

Keywords

How to Cite this Article?

References

If you have access to this article please login to view the article or kindly login to purchase the article

Purchase Instant Access

Options for accessing this content:

	North Americas,UK, Middle East,Europe		India	Rest of world
	USD	EUR	INR	USD-ROW
Pdf	35	35	200	20
Online	15	15	200	15
Pdf & Online	35	35	400	25